Different cytotoxic chemotherapy regimens are associated with varying rates of hospitalization following their use in older women with stage IV breast cancer.
The Short-HER study was unable to show noninferiority of 9 weeks of trastuzumab compared with the standard 1 year in women with HER2-positive breast cancer.
Nearly 10 years of follow-up from a large clinical trial have confirmed that axillary dissection is not necessary in patients with early breast cancer.
A study shows that combined hormonal contraceptive use is associated with a significant reduction in the risk of ovarian cancer.
The combination of encorafenib and binimetinib resulted in longer overall survival compared with vemurafenib in patients with BRAF V600–mutant melanoma.
A new proteomic analysis found that CT45 is an independent prognostic factor in patients with high-grade serous ovarian cancer, and a potential target of immunotherapies.
New research suggests that immune resistance in urothelial cancer may be mediated by stromal cells, which act as a source of EMT-related gene expression.
For patients with NETs that have metastasized to the liver, high levels of serum pancreastatin are predictive of poor outcomes after treatment with TACE.
Survival has increased substantially for young women with breast cancer since 1975, though it has largely reached a plateau since around 2005.
A dose-dense neoadjuvant chemotherapy regimen yielded higher response rates compared with a standard regimen in a cohort of bladder cancer patients.